Cohort Study to Evaluate the Efficacy and Safety of Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients with Muti-gene assay
Not Applicable
Recruiting
- Conditions
- HER2 Positive Elderly Breast Cancer Patients
- Registration Number
- JPRN-UMIN000051581
- Lead Sponsor
- Public Health Research Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 266
Inclusion Criteria
Not provided
Exclusion Criteria
Patient's physician determines that the patient is inappropriate to participate in this clinical trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence-free survival in the trastuzumab monotherapy group
- Secondary Outcome Measures
Name Time Method Overall Survival, Disease-Free Survival, Breast cancer-specific survival, RFS for trastuzumab alone and in combination with chemotherapy